Targeting Resistance Against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1580
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Trametinib: A MEK Inhibitor for Management of Metastatic Melanoma

OncoTargets and Therapy
OncologyPharmacology
2015English

The MEK Inhibitor Trametinib Ameliorates Kidney Fibrosis by Suppressing ERK1/2 and mTORC1 Signaling

Journal of the American Society of Nephrology : JASN
MedicineNephrology
2018English

Shipping Out MEK Inhibitor Resistance With SHP2 Inhibitors

Cancer Discovery
Oncology
2018English

Cellular Quiescence Caused by the Mdm2 Inhibitor Nutlin-3a

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2009English

U0126 Protects Cells Against Oxidative Stress Independent of Its Function as a MEK Inhibitor

ACS Chemical Neuroscience
BiochemistryMedicinePhysiologyCell BiologyCognitive Neuroscience
2015English

P53 Mediated Death of Cells Overexpressing MDM2 by an Inhibitor of MDM2 Interaction With P53

Oncogene
Cancer ResearchGeneticsMolecular Biology
1999English

The Physiological mTOR Complex 1 Inhibitor DDIT4 Mediates Therapy Resistance in Glioblastoma

British Journal of Cancer
Cancer ResearchOncology
2019English

Trametinib Modulates Cancer Multidrug Resistance by Targeting ABCB1 Transporter

Oncotarget
Oncology
2015English

PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells

Cancer Research
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy